Alia Abdelhameed is an Associate on the Therapeutics team. Ms. Abdelhameed joined the Firm in 2021 as a Fellow. She holds a B.E. in Biomedical Engineering with a minor in Physics from The City University of New York’s Macaulay Honors College.

Jaiti Swami is an Analyst on the Therapeutics team. Ms. Swami joined the Firm in 2021 as a Fellow. She holds a B.E. in Biomedical Engineering from The City University of New York’s City College.

Jason Fuller, Ph.D., is a Partner on the Therapeutics team and joined the Firm in 2021. Prior to Deerfield, Dr. Fuller was an investor at New Enterprise Associates (NEA), where he co-managed several investments in therapeutics, as well as in tools and diagnostics. Previous to NEA, he served as Head of Corporate Development at Jounce Therapeutics, one of several company formation projects he helped initiate in his role as Principal at Third Rock Ventures before joining Jounce. Dr. Fuller holds a B.S. in Chemical Engineering from Michigan State University, an M.Phil. from Cambridge University, and a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology, where he completed his degree in the lab of Robert Langer.

Joseph Pearlberg, M.D., Ph.D., is a Vice President of Scientific Affairs on the Therapeutics team and joined the Firm in 2017. Prior to Deerfield, Dr. Pearlberg was the Vice President of Clinical Development at Infinity Pharmaceuticals. Before Infinity Pharmaceuticals, Dr. Pearlberg worked as a Medical Director in the oncology unit of Sanofi. Dr. Pearlberg received his M.D. at the University of California, San Francisco, and completed his clinical training at the Massachusetts General Hospital and Dana Farber Cancer Institute. He earned his Ph.D. in Molecular Biology from Harvard University and was a Lecturer in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. He holds a B.A. in Biochemistry from the University of Pennsylvania.

Cameron Wheeler, Ph.D., is a Partner on the Therapeutics team and joined the Firm in 2014. Prior to Deerfield, Dr. Wheeler worked for and on behalf of Eleven Biotherapeutics, Inc. as a Director since 2009. Previous to that, he was Manager of the Business Development and Operations team at Constellation Pharmaceuticals and a Senior Associate at Third Rock Ventures. Dr. Wheeler holds a Ph.D. and S.M. in Biological Engineering and an S.B. in Mechanical Engineering from the Massachusetts Institute of Technology.

Howie Furst, M.D., is a Partner on the Therapeutics team and joined the Firm in 2007. Dr. Furst is a physician with eleven years of clinical experience. Prior to Deerfield, Dr. Furst was Portfolio Manager at Magnetar Capital and was responsible for building the firm’s healthcare team and developing its private and public investment approach. Before joining Magnetar, Dr. Furst served as a life sciences analyst at Maverick Capital. Dr. Furst received his B.A. with honors from the University of Pennsylvania, M.D. from New York University and M.B.A. from the Wharton School of the University of Pennsylvania.

Jonathan Leff is a Partner on the Therapeutics team at Deerfield and Chairman of the Deerfield Institute, and joined the Firm in 2013. He focuses on venture capital and structured investments in biotechnology and pharmaceuticals. Prior to Deerfield, for more than sixteen years, Mr. Leff was with Warburg Pincus, where he led the firm’s investment efforts in biotechnology and pharmaceuticals. He is a member of the Boards of several public and private healthcare companies as well as several not-for-profit organizations, including the Spinal Muscular Atrophy Foundation and the Columbia University Medical Center Board of Advisors, and has previously served as a director of the Reagan-Udall Foundation for the Food and Drug Administration. Mr. Leff has also been active in public policy discussions related to healthcare and medical innovation. He previously served as a member of the Executive Committee of the Board of the National Venture Capital Association (NVCA), where he led NVCA’s life sciences industry efforts as Chair of NVCA’s Medical Innovation and Competitiveness Coalition (NVCA-MedIC), and also previously served on the Board of the Biotechnology Innovation Organization. Mr. Leff holds an A.B. from Harvard University, an M.B.A. from Stanford University’s Graduate School of Business, and an M.S. in Biotechnology from Johns Hopkins University.

Nicholas Bishop, Ph.D., is a Partner on the Therapeutics team and joined the Firm in 2014. He provides extensive research and analysis on individual companies operating in the healthcare industry. Prior to Deerfield, Dr. Bishop spent four years as a research analyst covering the Biotechnology sector at Cowen and Company, where he was recognized as a Rising Star by Institutional Investor in 2013. Prior to entering the finance industry, Dr. Bishop was a biomedical research scientist at Harvard University and Massachusetts Institute of Technology. He has authored several scientific journal articles on the genetic regulation of aging and lifespan, one of which was featured as the cover story for an issue of Nature. Dr. Bishop received his B.A. with honors from Rice University and Ph.D. from the Massachusetts Institute of Technology.